SCHEMBL451716

SCHEMBL451716

COc1ccc(-n2c(C(C)N(C)C(=O)c3ccccc3OC)nc3ccccc3c2=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 6/20 0.56
PDE10A Q9Y233 4/20 0.56
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
ALDH1A1 P00352 3/20 0.50
RAB9A P51151 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL453380 0.92 SMN1; SMN2 (0.53) CXCR3PDE10AMEN1KMT2AALDH1A1
SCHEMBL449210 0.88 CXCR3 (0.59) CXCR3PDE10AMEN1KMT2AALDH1A1
SCHEMBL453845 0.84 CXCR3 (0.55) CXCR3PDE10AMEN1KMT2AALDH1A1
SCHEMBL450828 0.84 POLB (0.58) CXCR3PDE10AMEN1KMT2AALDH1A1
SCHEMBL450119 0.84 CXCR3 (0.55) CXCR3PDE10AMEN1KMT2AALDH1A1
SCHEMBL1552961 0.83 CXCR3 (0.54) CXCR3PDE10AMEN1KMT2AALDH1A1
SCHEMBL448566 0.79 ALDH1A1 (0.56) CXCR3PDE10AMEN1KMT2AALDH1A1
SCHEMBL451199 0.78 SMN1; SMN2 (0.50) CXCR3PDE10AMEN1KMT2AALDH1A1
SCHEMBL4579481 0.77 ALDH1A1 (0.59) CXCR3PDE10AMEN1KMT2AALDH1A1
SCHEMBL451745 0.77 CXCR3 (0.55) CXCR3PDE10AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP claimed
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors X-CEPTOR THERAPEUTICS, INC. (US) 2008-03-20 US claimed
US-8748440-B2 Quinazolinone modulators of nuclear receptors EXELIXIS, INC. (US) 2014-06-10 US disclosed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US disclosed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP disclosed
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors X-CEPTOR THERAPEUTICS, INC. (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 CXCR3 741/4885PDE10A 1893/4885MEN1 4424/4885
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 CXCR3 741/4885PDE10A 1893/4885MEN1 4424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.